References

References for Medical Providers

*A subscription to certain journals may be required to view full papers*

Treatment References:

April 2015, Annals of Oncology

Utility of 18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.           

http://www.ncbi.nlm.nih.gov/pubmed/25605745

February 2015, Annals of Oncology

Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center.      

http://www.ncbi.nlm.nih.gov/pubmed/25392158

January 2013, Journal of Clinical Oncology

Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.        

http://www.ncbi.nlm.nih.gov/pubmed/23109692

September 2012, Journal of Clinical Oncology

Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.     

http://www.ncbi.nlm.nih.gov/pubmed/22851556

August 2012, Clinical Lymphoma, Myeloma & Leukemia

(Cutaneous) Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.       

http://www.ncbi.nlm.nih.gov/pubmed/22542448

June 2012, Journal of Clinical Oncology

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.     

http://www.ncbi.nlm.nih.gov/pubmed/22614995

May 2012, Blood

(Cutaneous) Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.        

http://www.ncbi.nlm.nih.gov/pubmed/22394596

February 2012, Journal of Clinical Oncology

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.

http://www.ncbi.nlm.nih.gov/pubmed/22271479

March 2011, Journal of Clinical Oncology

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.

http://www.ncbi.nlm.nih.gov/pubmed/21245435

November 2010, Blood

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.       http://www.ncbi.nlm.nih.gov/pubmed/20660290

July 2010, British Journal of Haematology

Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas.     

http://www.ncbi.nlm.nih.gov/pubmed/20507311

May 2008, Journal of Clinical Oncology

Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire.       

http://www.ncbi.nlm.nih.gov/pubmed/18390969

September 2007, Journal of Clinical Oncology

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.        

http://www.ncbi.nlm.nih.gov/pubmed/17709797

Reviews:

October 2014, Cancer Treatment Reviews

Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.       

http://www.ncbi.nlm.nih.gov/pubmed/25199959

June 2013, Therapeutic Advances in Hematology

Novel therapies for peripheral T-cell lymphomas.        

http://www.ncbi.nlm.nih.gov/pubmed/23730495

March 2013, Best Practice & Research Clinical Haematology

Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.           

http://www.ncbi.nlm.nih.gov/pubmed/23768643